Cooley

Nate Gray

Associate

ngray@cooley.com

+1 415 693 2442

San Francisco

Venture Capital
Emerging Companies
Mergers and Acquisitions
Capital Markets
Artificial Intelligence
Life Sciences and Healthcare
Biotechnology
Medtech
Digital Health
Climate Tech

Nate focuses on representing emerging and growth-stage life sciences and tech companies throughout their life cycles – including corporate formation, venture capital, growth equity and cross-over financings, corporate spinouts, mergers and acquisitions and initial public offerings. His life sciences experience spans a range of biopharmaceutical technologies, tools, diagnostics, digital health and medical device technologies. He also represents private equity firms, venture capital firms and angel investors in investment transactions and portfolio company-related matters.

Nate is passionate about working with companies that are developing technological and scientific innovations that will transform industries and improve lives. He is a dedicated, responsive counselor and advocate for his clients, and seeks to be a long-term partner in the growth and success of his clients' businesses.

During law school, he was an Edward F. Hennessey Distinguished Scholar, a Paul J. Liacos scholar and an editor for the Boston University Law Review.

Representative matters

Nate's representative transactions include advising:

- Alamar Biosciences in its initial public offering, $56 million crossover financing, $128 million Series C financing, $80 million Series B financing and spinout of Attovia Therapeutics*
- BillionToOne in its initial public offering, $130 million Series D financing, $125 million Series C financing, $48.5 million equity and $35 million debt financing*
- Radar Therapeutics in its $13.4 million Series Seed financing *
- Reducto in its $75 million Series B
- Moonwalk Biosciences with its formation and $57 million Series A financing*
- Ancora Biotech LLC in its formation and $60 million Series A financing*
- Monarch Tractor, an electric tractor company, in its $133 million Series C financing*
- Neuron23 in its $100 million Series C financing*
- TeneoTwo in its sale to AstraZeneca for up to $1.27 billion*
- Star Therapeutics in its $90 million Series C financing*
- Electra Therapeutics in its $80 million Series B financing*

- RevenueCat in its $50 million Series C financing and acquisition of Dipsea*
- TeneoTwo in its sale to AstraZeneca for up to $1.27 billion*
- Miroculus, a microfluidics company, in its sale to INTEGRA Biosciences*
- A Fortune 500 biopharmaceutical company in its $30 million private investment in public equity (PIPE) investment in Gritstone bio in connection with a collaboration, license and option agreement to research and develop a vaccine-based immunotherapy treatment for HIV*
- A Fortune 500 biopharmaceutical company in its exclusive option to acquire Tizona Therapeutics, consisting of the acquisition by the company of a 49.9% equity interest in Tizona for $300 million, an option for the company to acquire the remaining equity interests of Tizona for $100 million, and up to $1.25 billion of potential future milestone payments to Tizona equity holders*
- A Fortune 500 biopharmaceutical company in its exclusive option to acquire Pionyr Immunotherapeutics, consisting of the acquisition by the company of a 49.9% equity interest in Pionyr for $275 million, an option for the company to acquire the remaining equity interests of Pionyr for $315 million, and up to $1.15 billion of potential future milestone payments to Pionyr equity holders

* Representation handled before joining Cooley.

Education

Boston University School of Law JD, magna cum laude, 2016

Kenyon College BA, cum laude, 2010

Admissions & Credentials

California

Memberships & Affiliations

Protect Our Winters